Bipartisan members of Congress are celebrating the House’s passage last week of amendments to extend a psychedelics research effort at the Department of Defense (DOD) for an additional six years and to codify provisions of a psychedelics executive order signed by President Donald Trump earlier this year.
Rep. Alexandria Ocasio-Cortez (D-NY) told Marijuana Moment that “one of the things that’s so important about the promise of psilocybin specifically is that it is one of the only substances that has shown early promise in treatment-resistant PTSD.”
“There are so many people that have tried every single path available to them in order to get the healthcare that they need and they have not been able to access that,” she said.
The newly approved psychedelics amendments are now attached to the House-passed version of the National Defense Authorization Act (NDAA) for Fiscal Year 2027, though it’s not yet clear how the Senate will address the issue or if the reforms will be enacted into law.
Ocasio-Cortez has long pushed for psychedelics and broader drug policy reform, saying she has been “introducing and supportive of these psilocybin measures—everything from allowing the study to descheduling in the NDAA for my entire time in Congress.”
To that
Read full article on Marijuana Moment
